ArticleFrontiers in physiology2026
Exercise-induced changes in hemostasis markers in marathon runners: effects of enzyme supplementation and determinants.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increases in hemostatic markers, indicators of thrombotic risk, have been reported following strenuous exercise; however, determinants of these responses remain poorly understood. This study aimed to determine whether supplementation with hydrolytic enzymes and flavonoids (Wobenzym Methods: This predefined subanalysis of the Enzy-MagIC trial was conducted within a prospective, randomized, double-blind, placebo-controlled trial. Participants were randomized (1:1) to receive WOB (rutoside 600-1200 mg/day, bromelain 540-1080 mg/day, trypsin 288-576 mg/day) or placebo for 1 week before and 2 weeks post-race, following a predefined dosing regimen. Blood samples were collected at baseline, immediately, 24 h, and 72 h post-race for analysis of D-dimer, plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), prothrombin fragment 1 + 2 (F1+2), thrombin generation (calibrated automated thrombography; CAT: lag time, peak thrombin, endogenous thrombin potential [ETP]), maximal platelet aggregation induced by adenosine diphosphate (MPADP), and platelet count. Results: Among 118 male runners (age 42 ± 11 years; WOB n = 64, placebo n = 54), no differences were observed between groups for any hemostatic marker (all p>0.05). D-dimer, PAI-1, tPA, F1+2, MPADP, and platelet count increased immediately post-race (all p<0.001) and returned toward baseline within 24 h. CAT lag time and peak thrombin increased at 24 h (both p<0.05), whereas ETP decreased immediately post-race (p<0.001). In multivariable analyses, ΔtPA was associated with finishing time and age, and ΔCAT lag time with body fat percentage (all p<0.05). Conclusion: WOB supplementation did not affect post-race hemostasis; however, marathon running induced hemostatic activation, partly driven by clinical and performance-related characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.